Appendix A. Natural mortality probabilities
Since the cost-effectiveness model uses a single-year time-step, five-year probabilities (P 5yr ) for natural mortality at a given age group were taken from literature 1 and converted to annual probabilities (P 1yr ) according to the following:
[1] P 1yr = 1 -(1 -P 5yr ) ^ (1/5)
These one-year probabilities are then associated with patients belonging to a particular age group (Table A1) . 
Appendix B. Fibrosis progression rate estimation
State transitions between stages of liver disease have been estimated in the literature many times. [2] [3] [4] [5] We chose to estimate progression rates from the Chronic Hepatitis Cohort Study (CHeCS) 6 because the CHeCS cohort contains a relatively large number of hepatitis C mono-infected individuals from the US who are born between 1945 and 1965, which is the population of greatest interest to our study. Simple statistics about the biopsy records from CHeCS are presented in Table B1 . The procedure used to estimate the progression rates from biopsy scores is described in detail by Yi et al. 2 Our implementation of the Yi et al. 2 estimation procedure carries two assumptions worth additional discussion. First, for a given sample of biopsies the average infection period is assumed to be the same for all biopsy scores. For this reason, we only estimate progression rates from CHeCS using each patient's first biopsy. Using the second and third biopsies would not be reasonable given the estimation procedure's necessary assumption of a single, average infection period. The second assumption is that initial fibrosis levels (fibrosis at the time of infection) is assumed to be F0. And by extension, this assumption imposes progression-only direction of disease development (i.e., any fibrosis regression cannot be accommodated). Estimation results are presented in Table B2 . As a check on the use of progression rates estimated from CHeCS, Table B3 presents annual transition probabilities between liver disease stages, calculated from CHeCS-based progression rates and also from recent sources from a meta-analysis of stage transition probabilities by Thein et al. 3 The
CHeCS-based rates are comparable to those developed in the literature. For this study, neither the disease progression rates from CHeCS nor those from the literature are adjusted for any characteristics, such as gender, age, or alcohol consumption. In this way, the disease progression rates estimated from CHeCS include the effects of all patient-level characteristics that may influence disease progression. Table B3 ensures us that CHeCS-based rates are reasonable given previous estimates from the literature. We also evaluate the cost-effectiveness model with CHeCS-based rates and literature-based rates to investigate whether the rates imply any economically-significant differences in outcomes.
Those model results are presented in Table B4 . The most important outcome in Table B4 is that the values are similar when comparing scenarios that utilize CHeCS-based transition probabilities and transition probabilities based on the "Mid" values from Thein et al. 3 Since the CHeCS-based rates are slightly lower than the "Mid" values from the literature, the cost effectiveness ratios using the progression rates calculated from CHeCS data are slightly higher. In our model, lower rates of disease progression produce lower disease burdens and thereby yield higher (i.e., less desirable) costeffectiveness ratios with respect to early treatment. This pattern can be observed in the "Low" and "High" progression rate-based scenarios. The greatest cost effectiveness ratios are produced using the lowest progression rate assumptions ("Low" from Thein et al.) , and the smallest cost-effectiveness ratios are produced using the most rapid progression rate assumptions ("High" from Thein et al.) . Notice in all but the "High" scenario, comparing treatment at F1 to F2 results in a dominated strategy when a patient starts at F0. proportional difference is applied to the transition probabilities calculated from HCV-infected patients in CHeCS, which is described in Appendix C to produce the model parameter for the probability of transitioning from compensated cirrhosis (F4) to one of the ESLD states. 
Appendix D. Effect of HCV status and ESLD on quality adjusted life years
In the base case scenario, HCV-infected patients are subjected to a reduction in quality of life of 2% relative to HCV-uninfected (Table D1 ). This is implemented in the model by using a multiplier of 0.98 on QALYs for HCV-infected individuals; which is to say, 0.98 is multiplied by the HCVuninfected QALY value associated with a given liver disease stage. An assumption that HCV infection status confers reductions in quality of life is consistent with previously published cost-effectiveness studies 9,10,11 as well as previous studies that measure health related quality of life. [12] [13] [14] In particular, our model is a clinical model, where HCV infection status is presumed to be known by the patient. So even though some studies have found negligible quality of life reductions associated with HCV-infected patients when the patient's HCV infection status is unknown to them, 15 our model only considers patients who have been diagnosed. As diagnosed patients, they may incur physical as well as psychological reductions in their quality of life due to either the knowledge of their HCV infection status, or the physical symptoms of infection, or both. Studies have documented the harmful effects of HCV infection on a patient's psychological well-being 16 as well as reductions in health related quality of life measurements following a positive diagnosis. 17 Furthermore, a portion of the reductions in quality of life from hepatitis C have been documented to rebound, or recover, following successful treatment and a patient's achieving a sustained virologic response.
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Appendix E. Cost-effectiveness calculations
Cost-effectiveness analysis has been used to evaluate health care interventions for decades. 20 This study applies these standard methods to a set of HCV-related treatment policies. The HCV treatment policies were characterized by the stage of liver fibrosis that a patient initiates HCV treatment.
Those stages were defined as being at F0, F1, F2, F3, or F4. After costs and health outcomes were estimated with the model, any pair of policies could be evaluated using the formula for incremental (or marginal) cost effectiveness:
Policy A and policy B could be, for example, initiating therapy at F2 and initiating therapy at F3.
The costs and outcomes used in equation 1 were estimated in the model using equations 2 and 3: [3]
Equation 3 sums up the QALYs from all the population compartments (p), early stage liver disease states (f), and end stage liver disease states (v). These annual amounts were discounted every
Appendix F. Comparing immediate treatment to no treatment
Some clinicians may be interested in results that represent a situation where delaying treatment is not an option. In such a case, the choice must be made to initiate HCV treatment at diagnosis or forego treatment altogether. Table F1 presents results centered on this possibility. Average cost-effectiveness ratios are calculated comparing treatment at a given fibrosis level to a no-treatment scenario. Appendix G: Additional sensitivity analyses
In addition to the sensitivity analyses presented in the main text, we also conducted additional multi-way sensitivity analyses which are presented in this appendix. We varied all epidemiologic parameters simultaneously such that all epidemiologic parameters were assumed to be favorable to treatment or unfavorable to treatment. Broad ranges were found between the ICERs values calculated from scenarios assuming high and low (or favorable and unfavorable) parameter assumptions when both economic and epidemiologic parameters were varied together. For the scenarios where patients were diagnosed and treated at F0, the largest ranges were found when the following parameter groups were varied: quality of life assumptions ($14,300/QALY and $211,782,000/QALY), treatment costs ($77,100/QALY and $793,500), and the discount rate ($34,200/QALY and $693,600/QALY) (Table   G1 ). * This table presents the incremental cost effectiveness ratios comparing two scenarios under a variety of parameter assumptions. For example, the first value in the row labeled "Liver disease stage transitions / Low" is $288,100, which states the incremental cost per QALY attained (the incremental cost-effectiveness ratio) for a patient with a starting fibrosis level of F0 is $288,100 when comparing initiating treatment at F0 versus initiating treatment at F1 (i.e., Tx at F0 vs. F1). Sensitivity analyses are organized by parameter group, assuming a 55-year-old hepatitis C patient, with treatment of hepatitis C characterized by a generalized all-oral, direct-acting antiviral. All costs are in US$2012. To simplify presentation, all numbers were rounded to nearest hundred. F0, F1, F2, and F3 = stages of liver disease; ESLD = end stage liver disease; QALY = quality-adjusted life-year; Tx = treatment. † In these scenarios, treatment at F1 is dominated by treatment at F0 so the ICERs presented compare treatment at F0 with treatment at F2. ‡ Within the "Quality of life assumptions" scenarios, the favorable scenario uses the high values for QALY (Table 1 ) associated with being HCV-uninfected and uses the low value for the QALY multiplier (Table 1) , thereby maximizing the difference between quality of life among infected and uninfected populations.
Appendix H. Additional threshold analyses
In this appendix, additional threshold analyses were conducted, where important assumptions in the model were varied. In particular, we solved for the threshold treatment cost, as was done in Figure 2 of the main text, while assuming high and low values for specific parameter groups and using two different ICER targets. The two ICER targets are $50,000/QALY and $100,000/QALY. From these results, a large range of treatment cost thresholds is observed. When just the QALY parameter values are varied, the treatment cost threshold ranges from $2,427 to $259,694 among the scenarios yielding $50,000/QALY. The results that yielded $100,000/QALY (final column in Table H1 ) produce greater threshold treatment cost values because the ICER target has doubled from $50,000/QALY to $100,000/QALY. * All costs are presented as US$2012. For example, in the row labeled "Treatment effectiveness" / "Low" the value 12,383 indicates a treatment cost of $12,383 per year (or per complete dose) yields a incremental cost effectiveness ratio of $50,000/QALY for the treatment of patients in F0 relative to F2 for a hepatitis C patient who is 55 years old. F0, F1, F2, F3, F4 = stages of liver disease; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year. a. Treatment policies being compared are F0 vs. F2, because treatment at F0 dominates treatment at F1. In all other cases, the policies being compared are F0 vs. F1.
We also investigated the treatment cost thresholds under different levels of fibrosis and patient ages (Table H2 ). The treatment cost thresholds among patients diagnosed with F2 liver fibrosis are greater than the corresponding treatment cost thresholds for patients diagnosed at F1 or F0. In general, a patient diagnosed in a later stage of liver disease (e.g., diagnosed at F1 or F2 relative to diagnosed at F0) are more likely to progress to end stage liver disease sequelae. Therefore, the benefits to a successful treatment are greater and the treatment cost that yields a given cost-effectiveness threshold are greater.
These results indicate that the range treatment costs that yield a particular cost-effective threshold vary substantially across fibrosis level, patient age, and the assumed cost-effectiveness threshold. Another recent study finds the cost effectiveness of triple therapy to be between $62,900 and $102,600
per QALY when comparing triple therapy to dual therapy among mildly fibrotic patients, and between $32,800 and $54,100 per QALY when comparing triple therapy to dual therapy among patients with advanced fibrosis. 31 In similar fashion, a study that compares all-oral therapy to conventional therapy (dual therapy for genotypes 2/3 and triple therapy for genotype 1) does so without specific regard to the incremental cost effectiveness of treatment at different fibrosis level. 26 In their base case, they find the cost effectiveness of all oral therapy versus triple therapy to be $44,500 per QALY. 26 Their study assumes an all-oral therapy regimen is similar in cost and in some cases less expensive than triple therapy, which would contribute lower cost-effectiveness ratios than would be produced using our base case assumptions. Both studies 26, 31 differ from our study because they evaluate different therapy types (comparing all-oral therapy to triple therapy or comparing triple therapy to dual therapy) while assuming a given distribution of fibrosis levels for their modeled population. Our study assumes a generalized treatment type (characterized by treatment cost and effectiveness) and evaluates the scheduling of this treatment with respect to liver disease progression.
The progression rates we used carry the assumptions that liver fibrosis regression does not occur among HCV-infected or HCV-uninfected patients, and that fibrosis progression does not occur among HCV-uninfected patients. Evidence for fibrosis regression, particularly among HCV-uninfected patients, is growing. 32, 33 Including the possibility of fibrosis regression among HCV-uninfected patients would make HCV treatment even more beneficial and might have improved the relative costeffectiveness of earlier initiation of treatment. Evidence is also growing for mortality associated with HCV-infected individuals for causes other than liver-related diseases. 34 The current model assumes HCV-related deaths occur only during the most advanced stages of liver diseases. If HCV infection causes or contributes to premature deaths from non-liver-related causes among patients, then our model's estimates of disease-related deaths are low and treatment cost-effectiveness may be underestimated. Finally, due to the focus of this study on the US baby-boomer cohort, this model considers neither the potential for re-acquiring infection (through on-going drug use) nor any herdimmunity effects among sustained responders who continue to inject drugs. The magnitude of these forces remains the subject of discussion [35] [36] [37] and may also vary between the context, location, and scope of a given study. As with the omission of fibrosis regression and additional non-liver-related mortalities, inclusion of herd immunity effects may make treatment more beneficial and thereby improve treatment cost-effectiveness. Since the threshold analysis assumes a given cost-effectiveness ratio and estimates a cost-effective level for a given model parameter (i.e., treatment cost), by underestimating treatment cost-effectiveness (via omitting of fibrosis regression, excess mortality, and herd immunity) we may under-estimate the corresponding threshold levels of treatment cost. Since fibrosis regression and excess mortality are emerging ideas in hepatitis C research, there was no widespread consensus on possible parameter values, therefore we judged the inclusion of these aspects in the cost-effectiveness model would be too tenuous until further consensus developed. In the case of herd-immunity, this aspect of viral hepatitis seemed to be an inappropriate assumption for our population of interest, who are older in age and presumed to be no longer susceptible to re-infection because either their risk behaviors have changed since their initial infection or the conduit for their infection (i.e., contaminated blood transfusion) has been resolved.
